This is a First Time in Human (FTIH) study to investigate the safety, tolerability and
pharmacokinetics (PK) of a) single, escalating and b) twice-daily 14 days repeat doses of
intranasal SB-705498 in healthy volunteers (HVT). The safety and tolerability of single
intranasal 498 dosing will be assessed and established before initiating the evaluation of
repeat intranasal 498 dosing.